Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB00569_nanopub.RAYSE7iavfF-UuwxgX-qrjOM6YLMkz4wzjNIS_-SNBwaY#assertion>. }
Showing items 1 to 23 of
23
with 100 items per page.
- drugbank:DB00569 type drugbank_vocabulary:Drug assertion.
- drugbank:DB00569 label "Fondaparinux sodium [drugbank:DB00569]" assertion.
- drugbank:DB00569 seeAlso DB00569 assertion.
- drugbank:DB00569 seeAlso fondaparinux.html assertion.
- drugbank:DB00569 seeAlso arixtra.htm assertion.
- drugbank:DB00569 identifier "drugbank:DB00569" assertion.
- drugbank:DB00569 description "Fondaparinux (Arixtra) is a synthetic pentasaccharide anticoagulant. Apart from the O-methyl group at the reducing end of the molecule, the identity and sequence of the five monomeric sugar units contained in fondaparinux is identical to a sequence of five monomeric sugar units that can be isolated after either chemical or enzymatic cleavage of the polymeric glycosaminoglycan heparin and heparan sulfate (HS). This monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Binding of heparin/HS to ATIII has been shown to increase the anti-coagulant activity of antithrombin III 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture, hip replacement and knee surgery); to prevent VTE in patients undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable angina (UA) and non-ST segment elevation myocardial infarction (NSTEMI); and in the management of ST segment elevation myocardial infarction (STEMI)." assertion.
- drugbank:DB00569 title "Fondaparinux sodium" assertion.
- drugbank:DB00569 bio2rdf_vocabulary:identifier "DB00569" assertion.
- drugbank:DB00569 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB00569 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB00569" assertion.
- drugbank:DB00569 bio2rdf_vocabulary:x-identifiers.org DB00569 assertion.
- drugbank:DB00569 drugbank_vocabulary:drugbank-id "APRD00500" assertion.
- drugbank:DB00569 drugbank_vocabulary:drugbank-id "DB00569" assertion.
- drugbank:DB00569 drugbank_vocabulary:x-cas cas:114870-03-0 assertion.
- drugbank:DB00569 drugbank_vocabulary:x-ahfs ahfs:20:12.04.92 assertion.
- drugbank:DB00569 drugbank_vocabulary:x-atc atc:B01AX05 assertion.
- drugbank:DB00569 drugbank_vocabulary:x-chebi chebi:31632 assertion.
- drugbank:DB00569 drugbank_vocabulary:x-dpd dpd:2245531 assertion.
- drugbank:DB00569 drugbank_vocabulary:x-kegg kegg:D01844 assertion.
- drugbank:DB00569 drugbank_vocabulary:x-pharmgkb pharmgkb:PA164746297 assertion.
- drugbank:DB00569 drugbank_vocabulary:x-wikipedia wikipedia:Fondaparinux_sodium assertion.
- drugbank:DB00569 drugbank_vocabulary:x-ndc ndc:0007-3230-02 assertion.